A Phase 2 Study of Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)

This is a Phase 2, single-arm, open-label study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.

Start Date11 Apr 2025

Sponsor / Collaborator

Corcept Therapeutics, Inc.

NCT05726292

/ RecruitingPhase 2IIT

A Randomized Phase II Trial of Neoadjuvant Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.

Start Date06 Jan 2025

Sponsor / Collaborator

The University of Chicago

NCT05257408

/ Active, not recruitingPhase 3

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

Start Date29 Jun 2022

Sponsor / Collaborator

Corcept Therapeutics, Inc.

[+1]

100 Clinical Results associated with Relacorilant

100 Translational Medicine associated with Relacorilant

100 Patents (Medical) associated with Relacorilant

Literatures (Medical) associated with Relacorilant

01 Aug 2025·PHYTOMEDICINE

Tanshinone IIA improved psychological stress-induced embryo implantation disorders by inhibiting GC/GR signaling and promoting angiogenesis

Article

Author: Fang, Qunying ; Zong, Lu ; Wang, Jiawei ; Han, Hui ; Zhao, Shiyu ; Shui, Lijun ; Chen, Shengyuan ; Li, Fangfang ; Meng, Ye ; Jin, Qi ; Wu, Limin ; Qiao, Zonghui

BACKGROUND:

The exact mechanism by which psychological stress leads to embryo implantation disorders remains unclear. Studies have shown that psychological stress is associated with elevated levels of glucocorticoids (GC). Successful embryo implantation is closely related to normal endometrial angiogenesis, a key process in the creation of a conducive environment for embryo implantation. Tanshinone IIA (Tan IIA), a compound derived from traditional Chinese medicine, promotes angiogenesis. This study aimed to elucidate how psychological stress impairs embryo implantation and explore the potential therapeutic effects of Tan IIA.

METHODS:

Female mice were randomly divided into seven groups: control, restraint stress, CORT125134 antagonizing glucocorticoid receptor (GR), 7.5, 15, 30 mg/kg Tan IIA, and aspirin. Open-field and elevated plus maze tests were employed to evaluate behavioral changes. The embryo implantation sites were quantified using trypan blue injection. Endometrial GC levels by ELISA, GR expression by RT-qPCR and WB, angiogenesis by HE and IHC, and angiogenic factors (VEGF, ANG2) by IF were measured. JC-1, ATP, p-DRP1^S616, and transmission electron microscopy were used to detect endometrial mitochondrial damage. Oxidative stress was determined through ROS, MDA, catalase, and GPX4 assays, and IF co-staining of CD31 with 4-HNE examined vascular oxidative injury. Endometrial receptivity was evaluated by LIF and integrin αvβ3 expression.

RESULTS:

Psychological stress significantly induced anxiety-like behavior, reduced implantation sites, impaired endometrial angiogenesis, triggered mitochondrial dysfunction and oxidative stress, and compromised endometrial receptivity via GC/GR signaling activation. Administration of Tan IIA effectively alleviated these stress-induced impairments in a dose-dependent manner, primarily by inhibiting GC/GR activation and GR nuclear translocation. Specifically, Tan IIA alleviated anxiety-like behavior, reduced the p-DRP1^S616/DRP1 ratio, restored MMP and ATP production, and attenuated mitochondrial vacuolization and crista disruption. In addition, Tan IIA markedly decreased the levels of ROS, MDA, and CAT, while enhancing the expression of GPX4, VEGF, ANG2, LIF, and integrin αvβ3.

CONCLUSION:

Psychological stress disrupted embryo implantation by activating the GC/GR signaling. Tan IIA effectively alleviated stress-induced implantation disorders by inhibiting the GC/GR signaling. This study highlights the therapeutic potential of Tan IIA as a promising candidate for stress-related implantation disorders.

01 Jun 2025·LANCET

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Article

Author: Colombo, Nicoletta ; Diakos, Connie ; Artioli, Grazia ; McCollum, Michael E ; Hopp, Elizabeth ; Garbaos, Gabriel ; Van Gorp, Toon ; De La Cueva, Helena ; Mileshkin, Linda ; Oaknin, Ana ; Monk, Bradley J ; Scandurra, Giuseppa ; Balázs, Boglárka ; Salutari, Vanda ; Kang, Sokbom ; Leiser, Aliza L ; Scaranti, Mariana ; Pai, Sachin G ; Slomovitz, Brian ; Devaux, Alix ; Cassani, Chiara ; Gladieff, Laurence ; Lee, Yong Jae ; O'Malley, David M ; Bagaméri, Andrea ; Vergote, Ignace ; Kaczmarek, Emilie ; Bodnar, Lubomir ; Kesner-Hays, Amanda ; You, Benoit ; Caruso, Giuseppe ; Churruca, Cristina ; de Carvalho Calabrich, Aknar Freire ; Jubb, Adrian M ; Lorusso, Domenica ; Kim, Jae-Weon ; Nicum, Shibani ; McClung, Emily ; Clamp, Andrew ; Olawaiye, Alexander B ; Gilbert, Lucy ; Pashova, Hristina I ; Tudor, Iulia Cristina ; Kim, Byoung-Gie

BACKGROUND:

Relacorilant, a first-in-class selective glucocorticoid receptor antagonist, increases a tumour's sensitivity to chemotherapy by reducing cortisol signalling. This study aimed to show whether the addition of relacorilant to nab-paclitaxel improves progression-free and overall survival in females with platinum-resistant ovarian cancer.

METHODS:

This randomised, controlled, open-label phase 3 trial (ROSELLA [GOG-3073/ENGOT-ov72]) was done at 117 hospitals and community oncology treatment centres in 14 countries across Australia, Europe, Latin America, North America, and South Korea. Patients had to be aged 18 years or older and had to have a confirmed diagnosis of platinum-resistant, epithelial (ie, high-grade serous, endometrioid, or carcinosarcoma with a ≥30% epithelial component) ovarian, primary peritoneal, or fallopian tube cancer; up to three previous lines of anticancer therapy and previous bevacizumab and disease progression or intolerance to the most recent therapy; measurable disease according to the Response Evaluation Criteria in Solid Tumours (RECIST; version 1.1); an Eastern Cooperative Oncology Group performance status of 0 or 1; and adequate organ function. Patients were assigned (1:1) to relacorilant (150 mg orally the day before, of, and after nab-paclitaxel infusion) plus nab-paclitaxel (80 mg/m² intravenously on days 1, 8, and 15 of each 28-day cycle) or nab-paclitaxel monotherapy (100 mg/m² intravenously on the aforementioned schedule). The dual primary endpoints were progression-free survival assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumours (version 1.1) and overall survival, and were assessed in all randomly assigned patients by intention to treat. The safety population included all randomly assigned patients who received at least one dose of the assigned treatment. This trial was registered at ClinicalTrials.gov, NCT05257408, and is ongoing.

FINDINGS:

Between Jan 5, 2023, and April 8, 2024, 381 patients were randomly assigned to the combination group (n=188) or to the nab-paclitaxel monotherapy group (n=193). Patients receiving relacorilant plus nab-paclitaxel had a statistically significant improvement in progression-free survival assessed by blinded independent central review compared with those receiving nab-paclitaxel monotherapy (hazard ratio 0·70 [95% CI 0·54-0·91]; median 6·54 months [95% CI 5·55-7·43] vs 5·52 months [3·94-5·88]; stratified log-rank p=0·0076). At the planned interim analysis, there was a clinically meaningful difference in overall survival with the addition of relacorilant to nab-paclitaxel (0·69 [95% CI 0·52-0·92]; 15·97 months [95% CI 13·47-not reached] vs 11·50 months [10·02-13·57]; log-rank p=0·0121). Adverse events were similar across study groups when adjusted for nab-paclitaxel exposure; no new safety signals were observed.

INTERPRETATION:

The addition of relacorilant to nab-paclitaxel prolonged progression-free survival and interim results also showed an improvement in overall survival. Together, the results position the combination of relacorilant and nab-paclitaxel as a potential new standard treatment for patients with platinum-resistant ovarian cancer.

FUNDING:

Corcept Therapeutics.

04 Nov 2024·ONCOLOGIST

Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study

Article

Author: Leal, Alexis D ; Skeel, Roland T ; Fountzilas, Christos ; Pashova, Hristina ; Mann, Grace ; Alese, Olatunji B ; Oberstein, Paul E ; Huyck, Timothy K ; Kio, Ebenezer A ; Noonan, Anne M ; Chiorean, Elena Gabriela ; Bahary, Nathan ; Borazanci, Erkut H ; Lee, Valerie ; Philip, Philip A ; Chung, Vincent ; Wainberg, Zev A ; Hanna, Wahid T ; Cardin, Dana B

Abstract:

Background:

Modulation of glucocorticoid receptor (GR) activity in tumor cells enhances chemotherapy efficacy. We evaluated the selective GR modulator relacorilant plus nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who had received at least 2 prior therapy lines.

Patients and Methods:

In this open-label, single-arm, phase III study, patients received once-daily oral relacorilant (100 mg, titrated to 150 mg in 25 mg increments/cycle) and nab-paclitaxel (80 mg/m2) on days 1, 8, and 15 of 28-day cycles. The primary efficacy endpoint was objective response rate (ORR) by blinded independent central review. Progression-free survival (PFS), overall survival (OS), target gene modulation, and safety were also assessed.

Results:

Of 43 patients enrolled, 31 were evaluable for ORR (12 did not reach first postbaseline radiographic assessment). An interim analysis to assess whether ORR was ≥10% showed no confirmed responses and the study was discontinued. Two (6.5%) patients attained unconfirmed partial responses and 15 (48.4%) had stable disease. Fourteen of 31 (45.2%) patients had reductions in target lesion size, despite prior nab-paclitaxel exposure in 12 of the 14. Median PFS and OS were 2.4 months (95% CI, 1.4-4.2) and 3.9 months (95% CI, 2.8-4.9), respectively. The most common adverse events were fatigue and nausea. RNA analysis confirmed that relacorilant plus nab-paclitaxel suppressed 8 cortisol target genes of interest.

Conclusion:

Relacorilant plus nab-paclitaxel showed modest antitumor activity in heavily pretreated patients with mPDAC, with no new safety signals. Studies of this combination in other indications with a high unmet medical need are ongoing.

News (Medical) associated with Relacorilant

15 Jul 2025

·pipelinereview.com

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, CA, USA I July 14, 2025 I Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary, selective cortisol modulator, relacorilant, to treat patients with platinum-resistant ovarian cancer. Corcept’s filing is based on positive data from its pivotal Phase 3 ROSELLA and Phase 2 trials. In these trials, patients who received relacorilant plus nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel monotherapy, with no need for biomarker selection. Relacorilant was well-tolerated, consistent with its known safety profile. Importantly, the type, frequency and severity of adverse events in the combination arms were similar to those in the nab-paclitaxel monotherapy arms. Relacorilant did not increase the safety burden of the patients who received it. “This submission is an important milestone for Corcept as we now have two New Drug Applications before the FDA: Relacorilant in combination with nab-paclitaxel as a treatment for people with platinum-resistant ovarian cancer and relacorilant as a treatment for patients with hypercortisolism,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. “Better treatment options are needed for the many patients living with these diseases. Our oncology and endocrinology business units are already working to make sure relacorilant is available immediately following regulatory approval.” About Relacorilant Relacorilant, an oral therapy, is a selective glucocorticoid receptor (GR) antagonist that modulates cortisol activity by binding to the GR but not to the body’s other hormone receptors. Corcept is developing relacorilant in ovarian cancer and a variety of other serious disorders, including endogenous hypercortisolism and prostate cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. It has been designated an orphan drug by the FDA and the European Commission (EC) for the treatment of hypercortisolism and by the EC for the treatment of ovarian cancer. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025 for relacorilant as a treatment for patients with hypercortisolism. About Cortisol’s Role in Oncology Cortisol plays a role in tumor growth through several mechanisms. It helps solid tumors resist chemotherapy by inhibiting cellular apoptosis — the tumor-killing effect chemotherapy is meant to stimulate. In some cancers, cortisol promotes tumor growth by activating oncogenes in the cells to which it binds. Cortisol also suppresses the body’s immune response, which weakens its ability to fight all diseases, including cancer. About Platinum-Resistant Ovarian Cancer Ovarian cancer is the fifth most common cause of cancer death in women. Patients whose disease returns less than six months after receiving platinum-containing therapy have “platinum-resistant” disease. There are few treatment options for these women. Median overall survival following recurrence is approximately 12 months with single-agent chemotherapy. Approximately 20,000 women with platinum-resistant disease are candidates to start a new therapy each year in the United States, with at least an equal number in Europe. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders, leading to the discovery of more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com . SOURCE: Corcept Therapeutics

Clinical ResultOrphan DrugNDAPhase 3Drug Approval

06 Jun 2025

·www.biospace.com

Corcept Claims Survival Benefit in ALS Despite Missed Endpoint

iStock, cagkansayin Analysts at Truist Securities called the mid-stage data a “mixed bag,” also flagging gastrointestinal adverse events. However, the readout is unlikely to be “incremental” to Corcept’s overall stock narrative. Corcept Therapeutics ’ investigational cortisol modulator dazucorilant failed to boost functional performance in patients with amyotrophic lateral sclerosis—but the biotech dug into the data Thursday and came away with overall survival benefits. Analysts at Truist Securities called the Phase II readout a “mixed bag” in an investor note on Thursday, adding that aside from the missed primary endpoint, dazucorilant also elicited “increased” gastrointestinal adverse events. “We would have liked to see some QoL [quality of life] assessments to better gauge commercial potential as discontinuation rates” seemed higher in the dazucorilant group versus placebo, they said. Still, Truist considered Thursday’s readout to be only “incremental” to Corcept’s overall stock narrative. The analyst firm does not include dazucorilant in its valuation for the biotech. Thursday’s data, presented at the 2025 annual meeting of the European Network to Cure ALS, showed no statistical separation between dazucorilant and placebo patients in terms of scores on the ALS Functional Rating Scale-Revised , a disease-specific severity score that evaluates patients’ disability and respiratory function, among other metrics. However, an exploratory analysis found that dazucorilant treatment significantly improved overall survival. At 24 weeks, five of 82 patients on placebo died, as opposed none of the 83 patients in the dazucorilant arm. At one year, treatment with dazucorilant cut the risk of death by 84% versus placebo. The biotech called this effect “pronounced” in its Thursday release. Given the mixed mid-stage findings, Corcept is currently “working with regulatory authorities” to determine the best path forward for dazucorilant, Bill Guyer, the company’s chief development officer, said in a prepared statement on Thursday. The ALS readout comes after Corcept earlier this week unveiled Phase III data for its selective glucocorticoid receptor antagonist relacorilant, which it combined with nab-paclitaxel to treat patients with platinum-resistant ovarian cancer. The findings, revealed in a late-breaking presentation at the recently concluded 2025 conference of the American Society of Clinical Oncology, showed that the relacorilant regimen cut the risk of disease progression by 30% versus nab-paclitaxel alone. Progression-free survival, the study’s primary endpoint, improved 29% in relacorilant-treated patients versus controls. As in the case of dazucorilant in ALS however, Truist analysts flagged potential safety concerns with relacorilant. “Based on investor conversations, concerns may be around tolerability pro relacorilant, which is numerically higher than nab-pac alone,” the analysts wrote in a June 2 note. “Nab-pac” is BMS’s formulation of the chemotherapy paclitaxel, sold as Abraxane. However, Truist noted that these safety signals could be due to the “greater duration of exposure to nab-pac” in patients receiving the combo therapy. “When adjusted for duration of exposure, common AEs including neutropenia and anemia are comparable between study arms,” they said. Overall, the analysts found relacorilant’s profile “favorable,” adding that they “expect approval with commercial traction.” Corcept plans to submit a regulatory application for relacorilant in the third quarter of this year.

Clinical ResultPhase 2ASCOPhase 3

05 Jun 2025

·www.fiercebiotech.com

Corcept unveils promising survival data from failed phase 2 ALS trial

The biopharma has since conducted an analysis at 12 months that it said showed this survival benefit has continued.\n Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering light by pointing to promising survival data.The biopharma revealed in December 2024 that the drug, called dazucorilant, had failed to demonstrate a reduction in the decline in motor skills and other functional criteria, while being linked to “substantially more gastrointestinal upset.” The midstage study saw 249 patients across the U.S., Canada and Europe receive either 150 mg or 300 mg of dazucorilant or placebo daily for 24 weeks.In a presentation at the European Network to Cure ALS 2025 annual meeting this week, Corcept included a table showing that the decline as measured by a functionality scale was broadly the same across both dazucorilant cohorts and the placebo group over 24 weeks.However, Corcept pointed out that patient survival—a secondary endpoint for the study—“significantly improved” among the 83 patients who received the 300 mg dazucorilant dose. None of these patients had died by week 24, Corcept noted, compared to two patients in the 150 mg arm and five patients who received placebo.The biopharma has since conducted an analysis at 12 months that it said showed this survival benefit has continued. Specifically, 14 patients in the 300 mg group had died by this point, compared to 23 deaths in the 150 mg group and 21 deaths in the placebo arm—equivalent to a hazard ratio of 0.16 for the 300 mg group and placebo groups.Speaking to Fierce at the American Society of Clinical Oncology meeting in Chicago this week, Adrian Jubb, M.D., Ph.D., Head of Oncology and Neurology Clinical Development at Corcept, said the company had not originally planned “to look at the data this way.”“Nonetheless, in a disease like this, when you see an endpoint that\'s really clinically meaningful, like survival, it makes you stop and think,” Jubb told Fierce. “And so we\'re now looking at the data in a much more positive light than simply a miss on a primary objective.” When it came to safety, this morning\'s data showed that 19% of patients in the 300 mg group experienced at least one severe treatment-emergent adverse event (TEAE), compared to 17% of the 150 mg group and 13% of the placebo cohort. No patients died as a result of a TEAE in the 300 mg group, compared to two patients in the 150 mg group and four patients in the placebo group. Overall, dazucorilant demonstrated “an acceptable safety profile,” according to Corcept, which pointed out that 92% of adverse events were mild to moderate in severity.“Medications that can extend life for patients with ALS are urgently needed,” Corcept’s Chief Development Officer Bill Guyer said in a June 5 statement. “We are working with regulatory authorities to determine the optimal path for advancing dazucorilant.”The Redwood City, California-based biotech markets the FDA-approved cortisol receptor blocker Korlym, also known as mifepristone, as a treatment for hyperglycemia caused by high cortisol levels in the blood. Corcept’s clinical-stage pipeline is headed up by relacorilant, an antiglucocorticoid that secured a phase 3 win in Cushing’s syndrome last year and is awaiting an FDA approval decision by the end of the year.The biotech was up more than 1.4% premarket Thursday morning on a $7.4 billion market cap.

Clinical ResultPhase 3Drug ApprovalPhase 2ASCO

100 Deals associated with Relacorilant

External Link

KEGG	Wiki	ATC	Drug Bank
D11336	Relacorilant	-	DB14976

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Platinum-Resistant Ovarian Carcinoma	NDA/BLA	United States	Corcept Therapeutics, Inc.	14 Jul 2025
Cushing Syndrome	NDA/BLA	United States	Corcept Therapeutics, Inc.	30 Dec 2024
Peritoneal Neoplasms	Phase 3	United States	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Argentina	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Australia	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Belgium	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Brazil	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Canada	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	France	Corcept Therapeutics, Inc.	29 Jun 2022
Peritoneal Neoplasms	Phase 3	Hungary	Corcept Therapeutics, Inc.	29 Jun 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03776812 (CTgov)	Phase 2	Recurrent Platinum-Resistant Primary Peritoneal Carcinoma \| Recurrent ovarian cancer \| Recurrent Primary Peritoneal Carcinoma ... View more	178	Nab-paclitaxel+Relacorilant (Arm A: Continuous Relacorilant Dosing)	lushnsebqb(fzvvidtusa) = zrlywvzqbk slesmvyzbe (qsqwbqmhwq, bvvuxpfvym - unvzoitfey) View more	-	30 Apr 2025
				Nab-paclitaxel+Relacorilant (Arm B: Intermittent Relacorilant Dosing)	lushnsebqb(fzvvidtusa) = itewgdkzch slesmvyzbe (qsqwbqmhwq, togxkhhkph - yirvfmpzph) View more
NCT03697109 (GRACE, CTgov)	Phase 3	Endogenous Cushing Syndrome	152	Relacorilant (Relacorilant (RW Phase))	cntujkpatt = bhfjyobzra fdjxghzbkk (aodpsxthol, pkkwdgadws - zgilecptxu) View more	-	24 Apr 2025
				Placebo (Placebo (RW Phase))	cntujkpatt = pnoknwfpqg fdjxghzbkk (aodpsxthol, jcpcavckpi - fmydhpxzbv) View more
NCT05257408 (ROSELLA, Company_Website) Manual	Phase 3	Platinum-Resistant Ovarian Carcinoma	381	Relacorilant + nab-paclitaxel	orheokhydp(hcdneodtkm) = wwfocxpggl vopxtaaede (qioxacvksr ) Met View more	Positive	31 Mar 2025
				Nab-paclitaxel	orheokhydp(hcdneodtkm) = gttjswkyxd vopxtaaede (qioxacvksr ) Met View more
NCT03604198 (BusinessWire) Manual	Phase 3	Cushing Syndrome	116	Relacorilant	bzzdujjntn(ctjfhndpym) = At month 24 of the study, patients exhibited clinically meaningful and statistically significant reductions in mean systolic blood pressure (10.0 mm Hg; p-value: 0.012) and mean diastolic blood pressure (7.3 mm Hg; p-value: 0.016), compared to their measurement at entry into the long-term extension study. ympqzpqnpy (vrtdwsljwx ) View more	Positive	16 Dec 2024
NCT03604198 (Company_Website) Manual	Phase 2	Cushing Syndrome	53	Relacorilant	nieqmctljc(blidyvfbeb) = zjoxuougco kdvivsxksx (bttdclaaoz ) View more	Positive	25 Nov 2024
NCT04308590 (GRADIENT, Biospace) Manual	Phase 3	Cushing Syndrome	137	relacorilant	ocgiukzscb(vqbdlcbbag) = pbrvximldb gmogrbbfzb (uqlhdwhohl ) Met	Positive	30 Oct 2024
				Placebo	ocgiukzscb(vqbdlcbbag) = xoryxryaci gmogrbbfzb (uqlhdwhohl ) Met
NCT02804750 \| NCT00280475 (Pubmed \| J Endocrinol Invest)	Phase 2	Cushing Syndrome factor VIII \| activated partial thromboplastin time \| platelet count ... View more	34	Relacorilant (Surgery)	pgxnofdroz(nehryngpgy) = loltazkydd glmzsjjwtu (tthvxpykwj )	Positive	21 Sep 2024
NCT03697109 (GRACE, ENDO2024)	Phase 3	Cushing Syndrome	152	Relacorilant 100 mg QD	hlkluathum(ggmpjdibxw) = meqfqximgh vscykjlowl (fpitcjxuwv, 6.7) View more	Positive	01 Jun 2024
NCT03697109 (GRACE, Company_Website) Manual	Phase 3	Cushing Syndrome	-	relacorilant	kztwuhssqy(hctcmnvntj) = GRACE met its primary endpoint of loss of blood pressure control in the randomized withdrawal phase among patients receiving relacorilant as compared to placebo hnbbefkfmc (guvgobdqsx ) Met View more	Positive	28 May 2024
				placebo
NCT03697109 (GRACE, GlobeNewswire) Manual	Phase 3	Endogenous Cushing Syndrome	152	relacorilant	xhjaumxrho(ylbfceyovm) = qqflrnjljd jolwpgdmxb (ctmxaktllr ) View more	Positive	22 Apr 2024
				relacorilant (withdrawal phase)	xhjaumxrho(ylbfceyovm) = lmfxhzkvlo jolwpgdmxb (ctmxaktllr ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis